METiS TechBio Lists on Hong Kong Stock Exchange, Raising HKD 2.1 Billion
METiS TechBio has become the world's first publicly listed AI powered drug delivery company after debuting on the Hong Kong Stock Exchange, announced in a press release. The company focuses on AI powered nanodelivery for large molecule biopharmaceuticals and raised more than HKD 2.1 billion through its global offering.
The listing, under stock code 7666.HK, marks the largest healthcare IPO fundraising in Hong Kong so far in 2026. The Hong Kong public offering was oversubscribed by over 6,900 times, locking up more than HKD 730 billion in subscription funds. The international placing received orders from more than 280 institutional investors and was oversubscribed 82 times.
The IPO was jointly sponsored by Jefferies, Deutsche Bank Securities Asia, and CITIC Securities Hong Kong. Eighteen cornerstone investors subscribed for a total of USD 148 million, with BlackRock leading the group with a USD 50 million allocation. Other participants included UBS Asset Management Singapore, Mirae Asset of South Korea, ORIX Corporation of Japan, and several Chinese public fund managers.
The company, founded six years ago, has become one of the fastest unicorns in China's AI pharmaceutical sector to reach an IPO milestone.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like AI Funding Brief or Daily AI Brief.
Also, consider following us on social media:
More from Funding
Nov 20 Archer, formerly hackajob, raises $10 million for its AI recruiting platform Nov 20 Protesters rally against Anthropic in New York and San Francisco on its stock market debut Nov 19 Anthropic's IPO could channel about $156 billion to charity, TechCrunch estimates Nov 19 Sierra reportedly in talks to raise at a $30 billion valuation Nov 19 Everful raises $48.5 million to build AI infrastructure for global commerceAI Funding Brief
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Meta Plans to Raise $95 Billion in Stock to Fund AI
Noetix Robotics Files Confidentially for Hong Kong IPO
Beijing Moves to Support Falling Chinese AI Shares
Altimeter's Brad Gerstner puts in for $5 billion of the Anthropic IPO
Isomorphic Labs Seeks $5 Billion at $50 Billion Valuation
Daily AI Brief: the AI news that matters, in your inbox.